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Background. Tuberculous meningitis (TBM) is the most severe form of extrapulmonary tuberculosis. We developed and 
validated prognostic models for 9-month mortality in adults with TBM, with or without human immunodeficiency virus (HIV) 
infection.
Methods. We included 1699 subjects from 4 randomized clinical trials and 1 prospective observational study conducted at 2 
major referral hospitals in Southern Vietnam from 2001–2015. Modeling was based on multivariable Cox proportional hazards 
regression. The final prognostic models were validated internally and temporally and were displayed using nomograms and a Web-
based app (https://thaole.shinyapps.io/tbmapp/).
Results. 951 HIV-uninfected and 748 HIV-infected subjects with TBM were included; 219 of 951 (23.0%) and 384 of 748 (51.3%) 
died during 9-month follow-up. Common predictors for increased mortality in both populations were higher Medical Research 
Council (MRC) disease severity grade and lower cerebrospinal fluid lymphocyte cell count. In HIV-uninfected subjects, older age, 
previous tuberculosis, not receiving adjunctive dexamethasone, and focal neurological signs were additional risk factors; in HIV-
infected subjects, lower weight, lower peripheral blood CD4 cell count, and abnormal plasma sodium were additional risk factors. 
The areas under the receiver operating characteristic curves (AUCs) for the final prognostic models were 0.77 (HIV-uninfected 
population) and 0.78 (HIV-infected population), demonstrating better discrimination than the MRC grade (AUC, 0.66 and 0.70) or 
Glasgow Coma Scale score (AUC, 0.68 and 0.71) alone.
Conclusions. The developed models showed good performance and could be used in clinical practice to assist physicians in 
identifying patients with TBM at high risk of death and with increased need of supportive care.
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Tuberculous meningitis (TBM) accounted for about 1%–5% of 
the 10.4 million new tuberculosis cases in 2015 and is the most 
severe manifestation of the disease, killing or disabling about 
half of those afflicted [1]. TBM is especially common in children 
and those infected with human immunodeficiency virus (HIV), 
in whom outcomes are poor [2]. In a trial conducted in Vietnam, 
approximately 30% of participants died during the 9-month 
study period, and 40% of the survivors had disabilities [3].
The British Medical Research Council (MRC) constructed the 
first TBM severity grades for use in the 1948 trial of streptomy-
cin [4]. Patients were subdivided, based on clinical experience 
rather than statistical derivation, into “early” (no clinical signs 
of meningitis or focal neurology and fully conscious), “medium” 
(patient’s condition falling between early and advanced) and 
“advanced” (extremely ill, in deep coma). With the introduc-
tion of the Glasgow Coma Scale (GCS) in 1974, these categories 
were modified to the following grading system: grade I  (GCS 
score 15; no focal neurological signs), grade II (GCS score 
11–14 or 15 with focal neurological signs), or grade III (GCS 
score ≤10) [5]. This grading system has become the most widely 
used classification for TBM severity. Despite the age of the MRC 
scale, and its lack of statistical derivation, improved and robust 
prediction models for poor outcomes (death and/or neurolog-
ical deficit) in TBM based on large cohort studies and rigorous 
statistical methods are still lacking. Among prognostic studies 
in TBM published in the last 20 years, the majority were based 
on a small number of subjects (ranging from 23 to 507), and 
modern prognostic modeling tools for handling missing data or 
model validation were rarely used [6–9].
The primary objective of this study was to develop and val-
idate novel robust prognostic models for 9-month mortality 
in adult patients with TBM, with or without HIV coinfection. 
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The models were based on a large data set of 1699 subjects (951 
HIV uninfected, 748 HIV infected) enrolled in 4 randomized 
controlled trials and 1 prospective cohort study conducted in 
Vietnam. In addition, we compared the predictive performance 
of the developed models with the MRC grading system and the 
GCS, both widely used in the assessment of TBM severity.
METHODS
Study Population
Study Participants
The study population comprised subjects enrolled in 5 TBM 
studies conducted between 2001 and 2015 at 2 tertiary refer-
ral centers in Ho Chi Minh City, Vietnam: Pham Ngoc Thach 
Hospital and the Hospital for Tropical Diseases [3, 10–13]. 
Detailed descriptions of the studies have been published else-
where [3, 10–13] and are summarized in Supplementary Table 
S1. All studies were approved by the Oxford Tropical Research, 
Hospital for Tropical Diseases, and Pham Ngoc Thach Hospital 
ethics committees.
Inclusion Criteria
The inclusion criteria for the 5 studies are provided in 
Supplementary Table S1. In brief, all 5 studies included adult 
subjects with a clinical diagnosis of TBM, defined as having 
>5 days of meningitis symptoms, nuchal rigidity, and cerebro-
spinal fluid (CSF) abnormalities suggestive of TBM; additional 
criteria were radiological evidence of tuberculosis on chest 
radiograph or brain scan or microbiological evidence of tuber-
culosis from specimens other than CSF. Diagnostic categories 
of definite, probable, or possible TBM were defined according 
to study-specific diagnostic criteria because the uniform TBM 
case definition became available only in 2010 [14]. All study 
participants were included in the pooled analysis except if they 
had a confirmed alternative diagnosis, a study drug administra-
tion error, or an unknown HIV status.
Laboratory Investigation
CSF specimens were stained and cultured by standard meth-
ods for pyogenic bacteria, mycobacteria, and fungi. In the last 
study [3], CSF was also tested with the Xpert MTB/RIF assay 
(Cepheid). Isolates of M. tuberculosis were tested for suscepti-
bility to isoniazid, rifampin, ethambutol, and streptomycin with 
the mycobacterial growth indicator tube method [15]. Baseline 
peripheral blood CD4 cell counts were measured for all HIV-
infected adults, using flow cytometry.
Antituberculosis and Adjunctive Treatment
Unless study participants were randomized to an experimen-
tal antituberculosis treatment, participants received a stand-
ard antituberculosis regimen consisting of isoniazid (5  mg/
kg/d; maximum, 300 mg/d), rifampin (10 mg/kg/d; maximum, 
600 mg/d), pyrazinamide (25 mg/kg/d; maximum, 2 g/d) and 
ethambutol (20  mg/kg/d; maximum, 1.2  g/d) or streptomy-
cin (20 mg/kg/d; maximum, 1 g/d) for 3 months, followed by 
rifampin and isoniazid at the same doses for another 6 months. 
Since 2005, all patients received adjunctive dexamethasone for 
the first 6–8 weeks of treatment [3].
Primary Outcome
The primary end point was overall survival during a 9-month 
follow-up period. Patients without documented death during 
the follow-up period were censored at 9 months or at the last 
date they were known to be alive, whichever was earlier.
Candidate Predictors
Candidate predictors were initially selected based on clinical 
judgment, their status as established risk factors in previous 
publications [6–9, 16–18], and completeness of the data. The 
number of predictors was further restricted based on a rule of 
thumb of requiring at least 10 events for each included predic-
tor variable or degree of freedom [19]. The final list of candi-
date predictors is presented in Supplementary Table S2. For all 
laboratory parameters and radiology assessments, we used the 
value recorded closest to enrollment (up to ±7 days from enroll-
ment). Of note, CSF total white blood cell count and CSF total 
lymphocyte count were strongly correlated; therefore, only CSF 
lymphocyte count was included as candidate predictor. 
Resistance is known to be an important independent predic-
tor of  death in subjects with TBM [20, 21]. However, unless ear-
lier isolates are available or rapid molecular tests are performed, 
information about a patients’ tuberculosis drug susceptibility is 
not available at enrollment. The main models therefore did not 
include resistance, but models with resistance were depicted in 
the Supplementary Materials. The cohort variable was included 
in the full model to represent the change in patient management, 
treatment, and standard of health care over the 15-years time 
span of the included studies. We decided to construct separate 
prognostic models for the HIV-uninfected and HIV-infected 
TBM populations, because they are clinically distinct populations 
and we expected that predictors may differ between them.
Statistical Analysis
Full details of the statistical analysis are described in the 
Supplementary Appendix S1. In brief, incomplete data were 
multiply imputed using multivariable imputation by chained 
equations (MICE) [22]. The statistical model of choice was mul-
tivariable Cox proportional hazards regression including all pre-
specified candidate predictors. We tested for potential nonlinear 
effects of continuous candidate predictors and for interactions, 
that is, effect modifications, between age and other candidate 
predictors. Two variable selection methods were used to simplify 
the model: (1) backward stepwise selection with a stopping rule 
based on Akaike’s information criterion and (2) the least abso-
lute shrinkage and selection operator (LASSO) [23]. 
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We combined model selection with bootstrapping and based 
the final models on the most frequently (≥60%) included vari-
ables across all imputed and bootstrap data sets [24]. We used 
the area under the cumulative/dynamic receiver operating 
characteristic (ROC) curve (AUC) [25] for 9-month mortality 
risk prediction to assess the discrimination of the models and 
calibration plots [26] and to visually assess how closely the pre-
dicted mortality probabilities agree with the observed mortality 
probabilities. Internal bootstrap validation was performed to 
correct measures of model performance for overfitting. In add-
ition, we performed temporal validation, wherein data from the 
most recent trial served as the test data set to validate models 
developed based on earlier studies. The final prognostic models, 
that is, the variable-selected models with the highest AUC, were 
implemented in a Web-based mortality calculator and graph-
ically depicted using nomograms [26]. All analyses were con-
ducted using R software, version 3.3.1 [27].
RESULTS
Baseline Characteristics of Study Participants
The 5 studies included a total of 1734 subjects, of which 1699 
were included for prognostic modeling (Supplementary Figure 
Table 1. Baseline Characteristics of Patients With Tuberculous Meningitis Included in the Pooled Database, Overall and By Human Immunodeficiency 
Virus Status
Characteristic
All Patients (N = 1699) HIV Uninfected (n = 951) HIV Infected (n = 748)
Total No.a No. (%)b Total No.a No. (%)b Total No.a No. (%)b
Cohort 1699 951 748
 Dexamethasone trial 534 (31.4) 436 (45.9) 98 (13.1)
 Fluoroquinolone trial 56 (3.3) 53 (5.6) 3 (0.4)
 TBM HIV cohort 58 (3.4) 0 (0) 58 (7.7)
 ART timing trial 248 (14.6) 0 (0) 248 (33.2)
 Intensified treatment trial 803 (47.3) 462 (48.6) 341 (45.6)
Age, median (IQR), y 1698 34 (27–45) 951 40 (27–56) 747 31 (26–35)
Female sex 1699 514 (30.25) 951 406 (42.7) 748 108 (14.4)
Weight, median (IQR), kg 1695 46 (41–51) 951 46 (42–52) 744 45 (40–50)
Received dexamethasone treatment 1699 1436 (84.5) 951 742 (78.0) 748 694 (92.8 )
Receiving ART at enrollment 745 124 (16.6) … … 745 124 (16.6)
MRC gradec 1698 951 747
 Grade I 588 (34.6) 327 (34.4) 261 (34.9)
 Grade II 743 (43.8) 448 (47.1) 295 (39.5)
 Grade III 367 (21.6) 176 (18.5) 191 (25.6)
Illness duration at study entry, median (IQR), d 1685 15 (10–30) 948 15 (10–26) 737 15 (9–30)
History of previous tuberculosis treatment 1658 236 (14.2) 922 88 (9.5) 736 148 (20.1)
Focal neurological signs present 1683 818 (48.6) 951 517 (54.4) 732 301 (41.1)
Temperature, median (IQR), °C 1697 37.6 (37.2–38.5) 950 37.7 (37.2–38.5) 747 37.5 (37.2–38.5)
Occurrence of seizures 1685 50 (3.0) 950 25 (2.6) 735 25 (3.4)
Laboratory values, median (IQR)
 Plasma sodium, mmol/L 1537 129 (124–133) 843 130 (125–134) 694 127 (123–132)
 CSF lymphocyte count, cells/μL 1614 85 (27.6–197.5) 919 94 (32.5–200) 695 73 (23.3–188.8)
 CSF protein, g/L 1624 1.3 (0.70–1.94) 909 1.2 (0.7–2.0) 715 1.3 (0.7–1.9)
 CSF glucose, mmol/L 1636 1.60 (1.05–2.30) 920 1.52 (1.00–2.30) 716 1.70 (1.17–2.33)
 Ratio of CSF to blood glucose 1470 0.30 (0.21–0.41) 830 0.30 (0.20–0.40) 640 0.30 (0.21–0.42)
Microbiologically confirmed/definite TBM 1699 823 (48.4) 951 361 (38.0) 748 462 (61.8)
Resistanced 1699 951 748
 No isoniazid or rifampin resistance 479 (28.2) 203 (21.4) 276 (36.9)
 Isoniazid monoresistance 172 (10.1) 63 (6.6) 109 (14.6)
 Rifampin monoresistance/MDR 35 (2.1) 10 (1.1) 25 (3.3)
 Unknown resistance 1013 (59.6) 675 (71.0) 338 (45.2)
Miliary tuberculosis present on chest radiograph 1525 279 (18.3) 890 165 (18.5) 635 114 (17.9)
Peripheral blood CD4 count, median (IQR), 
cells/μL
646 41 (16–108) … … 646 41 (16–108)
Abbreviations: ART, antiretroviral therapy; CSF, cerebrospinal fluid; HIV, human immunodeficiency virus; IQR, interquartile range; MDR, multidrug resistance; MRC, Medical Research Council; 
TBM, tuberculous meningitis.
aNo. of subjects with nonmissing data for the respective characteristic.
bData represent no. (%) of subjects unless otherwise specified.
cMRC grade I is defined as Glasgow Coma Scale (GCS) score 15 with no focal neurological signs; grade II, GCS score 11–14, or 15 with focal neurological signs; grade III, GCS score ≤10.
dIsoniazid monoresistance is defined as resistance to isoniazid but not to rifampin; MDR, as resistance to at least isoniazid and rifampin; unknown resistance, as drug-susceptibility test 
results not available. In all categories, resistance to other drugs may be present.
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S1). The reasons for excluding 35 subjects were a confirmed 
other diagnosis (n = 16), unknown HIV status (n = 16), or a 
study drug administration error (n = 3).
Table 1 presents the baseline characteristics of all included 
subjects; 951 were HIV uninfected (56.0%), and 748 (44.0%) 
were HIV infected. The median age was 34 years (interquar-
tile range, 27–45 years), and 823 subjects (48.4%) had defin-
ite, microbiologically confirmed TBM. The MRC grade was I in 
588 subjects (34.6%), II in 743 (43.8%), and III in 367 (21.6%). 
Among HIV-infected subjects, the median CD4 cell count was 
41 cells/μL, and 124 (16.6%) were receiving antiretroviral ther-
apy (ART) at baseline. Compared with HIV-uninfected subjects, 
those infected with HIV tended to be younger (median age, 31 
vs 40 years), were more frequently male (85.6% vs 62.3% male) 
and were more likely to be MRC grade III (25.6% vs 18.5%).
During 9-month follow-up, 219 of 951 HIV-uninfected sub-
jects with TBM (23.0%) died, compared with 384 of 748 HIV-
infected subjects (51.3%). Among the 1096 survivors, 998 
(91.1%) were followed up for ≥260 days. Yearly recruitment into 
the 5 studies and observed mortality rate by HIV status are shown 
in Figure 1. The figure displays a decline in mortality rate over 
time, which is particularly pronounced in HIV-infected subjects. 
In this subpopulation, the estimated 9-month mortality rate 
dropped from 52%–92% during 2001–2007 to 35%–50% during 
2011–2015. Coincidently, the number of study participant receiv-
ing ART at enrollment was only 7 of 407 (1.7%) in the first period 
and increased to 117 of 341 (34.3%) in the second period.
Prognostic Models
Univariable analyses of the effect of all candidate predictors 
for survival are shown in Supplementary Tables S3 and S4. 
Results of the multivariable analyses are shown in Table 2 and 
Supplementary Table S5. The final models identified higher 
MRC disease severity grade and lower CSF lymphocyte cell 
counts as risk factors for death in both HIV-uninfected and 
HIV-infected subjects (Table 2). Importantly, the mortality rate 
in MRC grade III (GCS score ≤10) was 3-fold higher in HIV-
uninfected patients and 4-fold higher in HIV-infected patients 
compared with MRC grade I (GCS score 15; no focal neurolog-
ical signs). Mortality rates for MRC grade II (GCS score 11–14, 
or 15 with focal neurological signs) was intermediate in both 
populations.
In HIV-uninfected subjects, older age, previous tuberculosis, 
not receiving adjunctive dexamethasone, and focal neurolog-
ical signs were additional predictors of higher mortality risk. 
Of note, the mortality rate was increased by >50% in patients 
with previous tuberculosis and those with focal neurological 
signs, and almost doubled for patients who did not receive 
dexamethasone.
In the HIV-infected population, lower weight, lower periph-
eral blood CD4 cell count, and abnormal plasma sodium were 
additional predictors of higher mortality. Plasma sodium had 
a significant nonlinear association with survival, and both 
decreased and elevated sodium values were associated with a 
higher predicted mortality rate compared with intermediate 
value values. Ongoing ART at enrollment was associated with a 
more favorable outcome in univariable analysis (Supplementary 
Table S4) but was no longer significantly associated with sur-
vival after adjustment for other factors. There was no clear evi-
dence that age modified the effect of any of the other predictors 
(overall interaction test, P = .14 in HIV-uninfected and P =.10 
in HIV-infected subjects).
Figure 1. Annual recruitment into the 5 contributing studies by human immunodeficiency virus status. Black lines show estimated 9-month mortality rates (as percentages) 
for each calendar year, based on the Kaplan-Meier method. Abbreviations: ART, antiretroviral therapy; HIV, human immunodeficiency virus; TBM, tuberculous meningitis.
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Model Validation
The final models showed good discrimination between TBM 
survivors and deaths at 9  months; the corresponding AUCs 
in internal validation (corrected for overfitting) were 0.77 in 
the HIV-uninfected and 0.78 in the HIV-infected population 
(Table 3). The addition of drug resistance as a covariate resulted 
in only a slightly improved model discrimination, with AUC 
values ranging from 0.77 to 0.79 (Supplementary Table S7).
In internal validation, the models showed good agreement 
between predicted and observed mortality (Supplementary 
Table 2. Final Cox Regression Models for 9-Month Survival in Each Human Immunodeficiency Virus Populationa
Variable
HIV-Uninfected TBM Population HIV-Infected TBM Population
Full Model Final Modelb Full Model Final Modelb 
HR 95% CI P Value HR 95% CI P Value HR 95% CI P Value HR 95% CI P Value
Age (per +10 y) 1.24 1.15–1.34 <.001 1.24 1.15–1.34 <.001 0.99 .85–1.16 .89 … … …
Male sex 1.07 .79–1.44 .67 … … … 0.95 .70–1.30 .77 … … …
Weight (per +10 kg) 0.88 .73–1.06 .17 … … … 0.72 .61–.85 <.001 0.73 .63–.85 <.001
MRC gradec
 Grade I 1 … … 1 … … 1 … … 1 … …
 Grade II 1.36 .87–2.13 .17 1.41 .9–2.19 .13 1.71 1.24–2.35 .001 1.88 1.43–2.48 <.001
 Grade III 2.97 1.83–4.83 <.001 3.05 1.92–4.86 <.001 3.76 2.69–5.26 <.001 4.08 3.07–5.41 <.001
Illness duration at study 
entry (d)d
1.03 .91–1.17 .61 … … … 1.02 .93–1.11 .73 … … …
History of previous  
tuberculosis treatment 
1.46 1.00–2.13 .05 1.57 1.09–2.26 .02 1.26 .97–1.65 .09 … … …
Focal neurological signs 
present
1.80 1.22–2.64 .003 1.65 1.15–2.39 .007 1.15 .87–1.53 .33 … … …
Temperature (°C) 0.96 .79–1.17 .71 … … … 1.09 .96–1.24 .18 … … …
Occurrence of seizures 0.96 .41–2.22 .92 0.95 .58–1.56 .83
No dexamethasone: 
treatment
1.67 1.15–2.40 .006 1.97 1.46–2.67 <.001 1.12 .68–1.85 .65 … … …
Plasma sodium (per 
+10 mmol/L)e
1.01 .85–1.21 .89 … … … … … <.001 … … <.001
 Plasma sodium, 135 vs 
125 mmol/L
1.01 .85–1.21 … … … … 1.09 .91–1.31 … 1.07 .90–1.28 …
 Plasma sodium, 115 vs 
125 mmol/L
0.99 .83–1.17 … … … … 1.63 1.31–2.04 … 1.06 1.29–2.00 …
CSF lymphocyte count 
(cells/μL)d
0.88 .82–.94 <.001 0.86 .81–.92 <.001 0.93 .87–.99 .02 0.93 .88–.98 .004
CSF protein (g/L)d 0.95 .84–1.07 .38 … … … 0.95 .85–1.06 .37 … … …
CSF glucose (mmol/L) 1.03 .87–1.23 .70 … … … 1.08 .98–1.19 .10 … … …
Ratio of CSF to blood 
glucosed
1.02 .81–1.28 .88 … … … 0.91 .77–1.08 .30 … … …
Miliary tuberculosis present 
on chest radiograph 
0.82 .56–1.18 .29 … … … 0.95 .70–1.29 .73 … … …
Peripheral blood CD4 
(cells/μL)d
… … … … … … 0.91 .85–.98 .01 0.9 .84–.96 .002
Receiving ART at enrollment … … … … … … 0.87 .60–1.26 .45 … … …
Cohort
 Intensified trial 1 … … … … … 1 … … 1 … …
 Dexamethasone trial 1.46 .94–2.27 .09 … … … 1.96 1.23–3.14 .005 1.72 1.25–2.37 <.001
 Fluoroquinolone trial 1.12 .51–2.46 .77 … … … … … … … … …
 TBM HIV cohort … … … … … … 2.58 1.63–4.06 <.001 2.64 1.81–3.84 <.001
 ART timing trial … … … … … … 1.78 1.28–2.47 <.001 1.71 1.34–2.19 <.001
Abbreviations: ART, antiretroviral therapy; CI, confidence interval; CSF, cerebrospinal fluid; HIV, human immunodeficiency virus; HR, hazard ratio. MRC, Medical Research Council; TBM, 
tuberculous meningitis.
aEstimates were pooled across multiply imputed data sets.
bThe final model for the HIV-uninfected population was selected using the least absolute shrinkage and selection operator (LASSO) method. The final model for the HIV-infected population 
was selected using stepwise backward model selection. The 95% CIs and P values for final models do not take into account the uncertainty of model selection.
cMRC grade I is defined as Glasgow Coma Scale (GCS) score 15 with no focal neurological signs); grade II, GCS score 11–14, or 15 with focal neurological signs); grade III, GCS score ≤10.
dHR per 2-fold increase.
eIn HIV-infected subjects, the effect of sodium levels on mortality rates was significantly nonlinear and modeled with a restricted cubic spline function with 2 df. To simplify interpretation 
of the corresponding regression coefficients, only HRs for 2 derived sodium contrasts from that model are given. P values for sodium values In the HIV-infected population are based on 
overall Wald tests of the restricted cubic spline function.
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Figure S2A and S2C). In temporal validation, calibration in the 
HIV-uninfected groups remained satisfactory, whereas in the 
HIV infected group models developed based on earlier studies 
systematically overestimated the actual mortality in the most 
recent trial (Supplementary Figure S2B and S2D).
Figure 2 shows predicted survival curves of the final simpli-
fied models in 4 risk groups defined using cutoff points at the 
16th, 50th, 84th percentiles of the prognostic index generated 
by these models [28]. They show strong prognostic separation 
across risk strata, good agreement between predicted survival 
curves and Kaplan-Meier estimates in the full data set, and mild 
to substantial risk overestimation in temporal validation in 
HIV-uninfected and HIV-infected subjects
Comparison of Prognostic Models With MRC Grade and GCS Alone
MRC grade and GCS predicted mortality rate similarly well (AUC, 
0.66–0.71) (Table  3). The corresponding ROC curves for MRC 
grade, GCS score, and the final models are shown in Figure 3. MRC 
grade and GCS score were both clearly inferior to the developed mul-
tivariable models in terms of discrimination (for all comparisons, P 
< .001 for tests of equality between AUC values), whereas discrimin-
ation did not differ significantly between MRC grade and GCS score 
(P = .23 in HIV-uninfected and P = .19 in HIV-infected subjects).
Nomograms and Web App for Mortality Rate Prediction
Figure 4 visualizes the final models as nomograms. For clinical 
use, this model has also been implemented as a user-friendly 
Web app (available at https://thaole.shinyapps.io/tbmapp/). We 
also generated nomograms for use when resistance information 
is available (Supplementary Figure S3). Of note, for creation of 
the nomogram and the Web app in the HIV-infected popula-
tion, the cohort variable was chosen as our most recent trial [3], 
because this is most relevant for future prediction.
DISCUSSION
We developed and validated prognostic models for 9-month 
mortality after TBM diagnosis in a large data set of 951 HIV-
uninfected and 748 HIV-infected patients with TBM. We found 
that a higher MRC grade and lower CSF lymphocyte cell counts. 
Predictors of death in both groups. MRC grade assesses the 
severity of neurological impairment and numerous studies have 
shown its strong association with poor outcome [29, 30]. The 
predictive value of lower CSF lymphocyte counts is intriguing. 
Others have recently found that higher CSF neutrophil count 
predicted death from TBM [31]; both findings reflect that the 
importance of neuroinflammation in determining outcome 
from TBM is poorly understood.
Additional risk factors for mortality in HIV-uninfected 
patients were older age, previous tuberculosis treatment, not 
receiving dexamethasone, and having focal neurological signs. 
In HIV-infected subjects, additional risk factors were lower 
weight, lower CD4 cell count, and abnormal plasma sodium 
level. These finding are consistent with results from previous 
published studied conducted in India [32], Hong Kong [17], 
Taiwan [8], Turkey [33], South Africa [34], and Brazil [35]. The 
inclusion of different predictors in the 2 HIV populations may 
suggest important differences in disease pathogenesis and out-
comes between these subgroups.
The main analysis did not include drug resistance as a covari-
ate because this information is often not available at enrollment. 
Table 3. Discrimination of Candidate Models for Tuberculous Meningitis Mortality By Human Immunodeficiency Virus Population Measured By Area 
Under the Curve at 9 Months
Model
Internal Validation
Temporal Validation: AUC (95% CI)Apparent AUC (95% CI)a Optimism-Corrected AUCb
HIV-uninfected population
 Full model 0.79 (.76–.83) 0.76 0.77 (.72–.83)
 Model selected by stepwise backward model selection 0.78 (.74–.81) 0.76 0.77 (.71–.82)
 Model selected by LASSO methodc 0.78 (.75–.82) 0.77 0.82 (.77–.87)
 MRC graded 0.66 (.62–.70) 0.66 0.70 (.64–.75)
 GCS 0.68 (.64–.72) 0.68 0.68 (.62–.75)
HIV-infected population
 Full model 0.79 (.75–.83) 0.77 0.76 (.70–.82)
 Model selected by stepwise backward model selectionc 0.79 (.75–.82) 0.78 0.73 (.67–.79)
 Model selected by LASSO method 0.78 (.74–.82) 0.77 0.75 (.69–.81)
 MRC graded 0.70 (.66–.74) 0.70 0.69 (.63–.75)
 GCS 0.71 (.67–.75) 0.71 0.68 (.62–.74)
Abbreviations: AUC, area under the cumulative/dynamic receiver operating characteristic curve; CI, confidence interval; GCS, Glasgow Coma Scale; HIV, human immunodeficiency virus; 
LASSO, least absolute shrinkage and selection operator; MRC, Medical Research Council.
aPerformance estimated directly from the original 45 imputed data sets used to develop the prediction models.
bAdjusted performance corrected for overoptimism through internal bootstrap validation.
cFinal simplified model.
dMRC grade I is defined as GCS score 15 with no focal neurological signs; grade II, GCS score 11–14, or 15 with focal neurological signs; and grade III, GCS score ≤10.
Figure 2. Comparison between predicted survival with the final models and observed Kaplan-Meier estimates. Risk groups are defined using cutoff points at the 16th, 
50th, and 84th percentiles of the prognostic index as generated by the final models (defining “good,” “fairly good,” “fairly poor,” and “poor” prognostic subgroups). (A) HIV-
uninfected TBM population, temporal validation; (B) HIV-infected TBM population, temporal validation; (C) HIV-uninfected TBM population, all multiply imputed data; (D) 
HIV-infected TBM population, all multiply imputed data. Abbreviations: HIV, human immunodeficiency virus; KM, Kaplan-Meier; TBM, tuberculous meningitis. 
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Figure 2. Comparison between predicted survival with the final models and observed Kaplan-Meier estimates. Risk groups are defined using cutoff points at the 16th, 
50th, and 84th percentiles of the prognostic index as generated by the final models (defining “good,” “fairly good,” “fairly poor,” and “poor” prognostic subgroups). (A) HIV-
uninfected TBM population, temporal validation; (B) HIV-infected TBM population, temporal validation; (C) HIV-uninfected TBM population, all multiply imputed data; (D) 
HIV-infected TBM population, all multiply imputed data. Abbreviations: HIV, human immunodeficiency virus; KM, Kaplan-Meier; TBM, tuberculous meningitis. 
Figure 3. Cumulative/dynamic receiver operating characteristic curves (apparent estimate) for mortality rates evaluated at 9 months for the final prognostic model, 
Glasgow Coma Scale (GCS) score, and Medical Research Council (MRC) grade in the tuberculous meningitis populations with or without human immunodeficiency virus 
infection. MRC grade I is defined as GCS score 15 with no focal neurological signs; grade II, GCS score 11–14, or 15 with focal neurological signs; grade III, GCS score ≤0.  (A) 
HIV-uninfected TBM population; (B) HIV-infected TBM population. Abbreviations: GCS, Glasgow Coma Scale; HIV, human immunodeficiency virus; MRC, Medical Research 
Council; TBM, tuberculous meningitis.
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Alternative models including drug resistance showed only rel-
atively little improvement in model performance, especially in 
HIV-uninfected subjects. However, we note that the low prev-
alence in our cohort of multidrug-resistant tuberculosis, an 
important predictor of poor outcome in TBM [20, 21], may 
have contributed to this finding.
The final prediction models were carefully developed and 
validated with proper statistical methods [36]. They showed 
good discrimination between TBM survivors and patients who 
died in both internal and temporal validation, with substan-
tial improvement over the MRC grade or the GCS score alone. 
Although our models had excellent calibration in internal val-
idation, they overestimated mortality rates in temporal valida-
tion where the model was developed from earlier studies and 
tested on subjects included in the most recent trial. This over-
estimation was mild in HIV-uninfected subjects but substantial 
in HIV-infected subjects. It may be explained by improvements 
in treatment, especially the availability of ART, and patients’ 
supportive care over time. Importantly, because ART did not 
become widely available in Vietnam until 2005 [37] and receiv-
ing ART was an exclusion criterion for the ART timing trial, the 
intensified treatment trial [3] was the only study that included 
subjects receiving ART at TBM diagnosis. Therefore, the effect 
of ART was neglected in the temporal validation, which may 
have contributed to the observed overestimation. Temporal het-
erogeneity was addressed by including the cohort as a covariate 
in the statistical regression models. Survival for future patients 
is anticipated to be close to predictions adjusted to our most 
recent study.
Our study has several limitations, mostly owing to the char-
acteristics of our database. First, CSF lactate, which may be an 
important risk factor [38], was not taken into account in our final 
model because it was missing in >40% of subjects. Second, pre-
vious studies suggested that leukotriene A4 hydrolase (LTA4H) 
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Figure 4. Nomograms for the prediction of 9-month mortality based on the final prognostic models for the tuberculous meningitis populations without (A) or with (B) human 
immunodeficiency virus (HIV) infection. To derive a prediction, locate the value of each predictor on the corresponding variable line, read the corresponding points assigned 
on the 0–100 scale, and sum all of these points to a total point score. Then read the result on the “total points” scale and its corresponding prediction below. For HIV-infected 
population, the cohort variable was chosen as the most recent trial [3], because this is most relevant for future prediction. Abbreviations: CSF, cerebrospinal fluid; HIV, human 
immunodeficiency virus; MRC, Medical Research Council; TBM, tuberculous meningitis.
genotype is a determinant of the inflammatory response in HIV-
uninfected adults with TBM and consequently might predict 
who benefits from adjunctive corticosteroid treatment [39]. This 
factor may therefore influence survival in HIV-uninfected sub-
jects with TBM. Because the information of LTA4H genotype 
was not available for all included studies, we did not consider 
this covariate in our analyses. Third, the models were developed 
and validated based on data from 2 large hospitals in Southern 
Vietnam only. Thus, it would be desirable to validate and possibly 
improve our models in an independent external database. Finally, 
our models included only risk factors available at TBM diagnosis. 
However, changes in biomarkers repeatedly measured during the 
disease course may carry important information that could allow 
an initial prognosis to be updated and improved during tubercu-
losis treatment. The value of such longitudinally measured bio-
markers will be examined in a future research project.
Our final models were displayed as nomograms and imple-
mented in a user-friendly Web-based risk calculator (https://thaole.
shinyapps.io/tbmapp/) for use in clinical practice to improve prog-
nostic stratification in patients with TBM. Patients at high risk could 
be identified early and then monitored more strictly to receive 
appropriate counseling or supportive care, or enrolled in future clin-
ical trials exploring novel treatments targeted to severe TBM.
Our models are based on one of the largest sources of pro-
spectively collected clinical data for TBM disease worldwide. 
The final prognostic models included variables that are usually 
available for patients with TBM. Overall, our prediction mod-
els have good discrimination and calibration performance, and 
they clearly outperformed the MRC grading score.
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